trending Market Intelligence /marketintelligence/en/news-insights/trending/vsgM1qNNA60svNgxOVQ2zA2 content esgSubNav
In This List

Repros Therapeutics not eligible for extra time to regain Nasdaq compliance

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Repros Therapeutics not eligible for extra time to regain Nasdaq compliance

Nasdaq Stock Market LLC notified Repros Therapeutics Inc. that due to continued noncompliance with the minimum bid price rule, the company is not eligible for an additional 180-day extension to regain compliance.

Further, the determination serves as an additional basis for delisting the company's securities from the exchange.

The current notice has no effect on the listing of the company's common stock.

The company has also been noncompliant with the minimum stockholders' equity requirement, and had earlier requested a hearing before the Nasdaq hearings panel. An oral hearing is set for Jan. 18, 2018.